Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Manchester United PLC (MANU) Price & Performance

Bio-Rad Laboratories, Inc. Class A Common StockTrade
Manchester United PLCTrade

Price performance (Past 24H)

Key statistics

Bio-Rad Laboratories, Inc. Class A Common Stock vs Manchester United PLC — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.43B), while Manchester United PLC trades at $22.23 (market cap $3.80B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is far larger — about 2.5× Manchester United PLC's market cap, and Manchester United PLC pays a 1.26% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.

BIOMANU
Market Cap
$9.43B$3.80B
Sector
HealthMedia
52-Week High
$356.25$23.53
52-Week Low
$241.71$15.10
Enterprise Value
$9.18B$4.74B
Dividend Yield
1.26%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories (BIO) trades at $362.08, up 2.13% daily, near its 52-week high. The stock shows a bullish technical trend with strong moving averages, though RSI indicates overbought conditions. Fundamentally, Q2 2026 earnings beat estimates with EPS of $2.62 versus $1.75 expected, and revenue remains stable around $2.6 billion. Net income turned positive in 2025 after prior losses, with a current net margin of 29.41%. Analyst consensus is Buy with a $350 price target, and institutional holdings increased, as noted by Amundi's 1,763.4% stake growth per SEC filing on August 5, 2026.

Outlook is cautiously optimistic with solid earnings recovery and institutional support, but risks include high P/E of 43.39, potential overvaluation, and reliance on academic research markets. Investors should weigh strong profitability against valuation concerns and monitor upcoming Q3 earnings for sustained growth.

Manchester United PLC

Manchester United (MANU) trades at $22.88, up 5.44% on the day, with a bearish technical signal. The company reported a net loss of $33.02M for 2025, though revenue grew to $666.51M. Recent news highlights the acquisition of land for a new 100,000-seat stadium as a significant long-term de-risking milestone. Cash flow from operations remains positive at $72.70M, but negative profitability metrics and high debt levels persist.

The outlook is mixed; stadium development and Champions League qualification offer growth catalysts, but consistent net losses and weak margins pose fundamental risks. Analyst consensus is neutral with a 60% hold rating. The stock's trajectory hinges on successful execution of cost reductions and capitalizing on new revenue streams from the stadium project.

Returns comparison

Trailing returns across standard periods

About Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Read more on BIO

About Manchester United PLC

Manchester United PLC operates a professional football club together with related and ancillary activities. The company manages the soccer team and all affiliated club activities of the Manchester United Football Club, which includes the media network, foundation, fan zone, news, sports features, and team merchandise. Manchester United is based in England. The company has three principal sectors from which most of the revenue is generated, including Commercial, Broadcasting, and Matchday.

Read more on MANU